|
|
Blood, 15 October 2006, Vol. 108, No. 8, pp. 2796-2803.
Prepublished online as a Blood First Edition Paper on July 6, 2006; DOI 10.1182/blood-2006-04-017434.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma
Yajun Han,
Hesham M. Amin,
Bevin Franko,
Christine Frantz,
Xinzhe Shi, and
Raymond Lai
From the Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada; and Department of Hematopathology, the University of Texas M. D. Anderson Cancer Center, Houston.
Previous studies showed that most cases of ALK+ anaplastic large-cell lymphoma (ALK+ALCL) do not express SHP1, a tyrosine phosphatase and an important negative regulator for cellular signaling pathways such as that of JAK/STAT. To fully assess the biologic significance of loss of SHP1 in ALK+ALCL, we transfected SHP1 plasmids into 2 SHP1-, ALK+ALCL cell lines, Karpas 299 and SU-DHL-1. After 24 hours of transfection, pJAK3 and pSTAT3 were decreased, and these changes correlated with down-regulation of STAT3 downstream targets including cyclin D3, mcl-1, and bcl-2. Expression of SHP1 in these 2 cell lines also resulted in marked decreases in the protein levels of JAK3 and NPM-ALK, and these effects were reversible by proteosome inhibitor MG132. Conversely, when SHP1 expression in SUP-M2 (a SHP1+ ALK+ALCL cell line) was inhibited using siRNA, pSTAT3, pJAK3, JAK3, and NPM-ALK were all up-regulated. Coimmunoprecipitation studies showed that SHP1 was physically associated with JAK3 and NPM-ALK. SHP1 expression in Karpas 299 and SU-DHL-1 led to significant G1 cell cycle arrest but not apoptosis. To conclude, loss of SHP1 contributes to the pathogenesis of ALK+ALCL by 2 mechanisms: (1) it leaves the tyrosine phosphorylation and activation of JAK3/STAT3 unchecked and (2) it decreases proteosome degradation of JAK3 and NPM-ALK.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
ALK-mediated oncogenesis: mechanisms that matter
- Stephan W. Morris
Blood 2006 108: 2500-2501.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
M. K. Pandey, B. Sung, K. S. Ahn, and B. B. Aggarwal
Butein Suppresses Constitutive and Inducible Signal Transducer and Activator of Transcription (STAT) 3 Activation and STAT3-Regulated Gene Products through the Induction of a Protein Tyrosine Phosphatase SHP-1
Mol. Pharmacol.,
March 1, 2009;
75(3):
525 - 533.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Wu, P. Wang, L. C. Young, R. Lai, and L. Li
Proteome-Wide Identification of Novel Binding Partners to the Oncogenic Fusion Gene Protein, NPM-ALK, using Tandem Affinity Purification and Mass Spectrometry
Am. J. Pathol.,
February 1, 2009;
174(2):
361 - 370.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. Kunnumakkara, A. S. Nair, B. Sung, M. K. Pandey, and B. B. Aggarwal
Boswellic Acid Blocks Signal Transducers and Activators of Transcription 3 Signaling, Proliferation, and Survival of Multiple Myeloma via the Protein Tyrosine Phosphatase SHP-1
Mol. Cancer Res.,
January 1, 2009;
7(1):
118 - 128.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. S. Ahn, G. Sethi, B. Sung, A. Goel, R. Ralhan, and B. B. Aggarwal
Guggulsterone, a Farnesoid X Receptor Antagonist, Inhibits Constitutive and Inducible STAT3 Activation through Induction of a Protein Tyrosine Phosphatase SHP-1
Cancer Res.,
June 1, 2008;
68(11):
4406 - 4415.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. M. Amin and R. Lai
Pathobiology of ALK+ anaplastic large-cell lymphoma
Blood,
October 1, 2007;
110(7):
2259 - 2267.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. K. Pathak, M. Bhutani, A. S. Nair, K. S. Ahn, A. Chakraborty, H. Kadara, S. Guha, G. Sethi, and B. B. Aggarwal
Ursolic Acid Inhibits STAT3 Activation Pathway Leading to Suppression of Proliferation and Chemosensitization of Human Multiple Myeloma Cells
Mol. Cancer Res.,
September 1, 2007;
5(9):
943 - 955.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H M Kocher, L Mears, N C Lea, K Raj, and G J Mufti
JAK V617F missense mutation is absent in pancreatic cancer
Gut,
August 1, 2007;
56(8):
1174 - 1175.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bhutani, A. K. Pathak, A. S. Nair, A. B. Kunnumakkara, S. Guha, G. Sethi, and B. B. Aggarwal
Capsaicin Is a Novel Blocker of Constitutive and Interleukin-6-Inducible STAT3 Activation
Clin. Cancer Res.,
May 15, 2007;
13(10):
3024 - 3032.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|